Metastatic Pancreatic Adenocarcinoma (mPDAC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Metastatic Pancreatic Adenocarcinoma (mPDAC) Market Outlook
Thelansis’s “Metastatic Pancreatic
Adenocarcinoma (mPDAC) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Metastatic
Pancreatic Adenocarcinoma (mPDAC) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Metastatic Pancreatic Adenocarcinoma
(mPDAC) Overview
Pancreatic
Cancer (PC) is a lethal malignancy, with its prevalence, although relatively
low, steadily increasing each year. Metastatic PC, categorized as late-stage
(stage IV), represents the most advanced form of the disease, boasting an even
higher fatality rate compared to other stages. Notably, patients affected by PC
typically lack specific clinical manifestations. The major signaling pathways
in metastatic pancreatic cancer include Epithelial-Mesenchymal Transition (EMT)
and NF-κB (nuclear factor-κ-light-chain-enhancer activated B cells). Upon
diagnosis, it is frequently observed that PC has already metastasized to a
significant extent, rendering curative surgery unfeasible. However, imaging
techniques such as CT, utilizing X-rays to generate cross-sectional images of
the body, play a pivotal role in accurately assessing metastatic spread and
offering crucial insights into treatment strategies, especially for tumors on
the borderline of resectability. With the advanced stage and widespread
dissemination characteristic of metastatic PC, surgical removal as a treatment
modality is often not feasible.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment